Expression of cell cycle control proteins in primary colorectal tumors does not always predict expression in lymph node metastases

J A McKay, J J Douglas, V G Ross, S Curran, F Y Ahmed, J F Loane, G I Murray, H L McLeod

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Analysis of tumor markers focuses on expression in primary tumors with the assumption that this is representative of metastatic tumor, against which treatment is targeted. Few studies have compared the expression of such markers in primary and secondary tumors, In this study, several key genes involved in cell cycle regulation were investigated in colorectal tumors and corresponding lymph node metastases, The cell cycle regulators p53, cyclin D1, p21, p27, retinoblastoma protein (Rb), and proliferating cell nuclear antigen (PCNA) were examined in a series of 42 paired samples of primary colorectal and secondary lymph node tumors by immunohistochemistry. Expression of p53, p27, and Rb was similar in virtually all paired samples (p53, 38 of 42; p27, 39 of 42; Rb, 40 of 42), indicating that the pattern of these proteins in colorectal tumors may be used to predict that in lymph node tumors. It also suggests a lack of direct involvement in the metastatic process. A lower concordance for p21 and cyclin D1 staining was observed between primary and secondary tumors (p21, 19 of 42; cyclin D1, 22 of 42), p21 expression was more often observed in primary colorectal cancers, whereas cyclin D1 expression was more frequently seen in lymph node metastases, in keeping with the contrasting roles of these proteins as a cell cycle inhibitor (p21) and activator (cyclin D1). The PCNA-labeling index was found to vary considerably in a number of cases, thus limiting the ability to predict expression of this protein in lymph node metastases from the primary tumor. In addition, PCNA-labeling indices between paired samples were neither consistently higher nor lower, suggesting that the proliferative capacity of tumor cells is not directly related to their ability to metastasize.

Original languageEnglish
Pages (from-to)1113-1118
Number of pages6
JournalClinical Cancer Research
Volume6
Publication statusPublished - 2000

Keywords

  • NUCLEAR ANTIGEN PCNA
  • GENE-EXPRESSION
  • CANCER
  • P53
  • D1
  • ADENOCARCINOMAS
  • PROGNOSIS
  • IMMUNOHISTOCHEMISTRY
  • OVEREXPRESSION
  • PROLIFERATION

Cite this

McKay, J. A., Douglas, J. J., Ross, V. G., Curran, S., Ahmed, F. Y., Loane, J. F., ... McLeod, H. L. (2000). Expression of cell cycle control proteins in primary colorectal tumors does not always predict expression in lymph node metastases. Clinical Cancer Research, 6, 1113-1118.

Expression of cell cycle control proteins in primary colorectal tumors does not always predict expression in lymph node metastases. / McKay, J A ; Douglas, J J ; Ross, V G ; Curran, S ; Ahmed, F Y ; Loane, J F ; Murray, G I ; McLeod, H L .

In: Clinical Cancer Research, Vol. 6, 2000, p. 1113-1118.

Research output: Contribution to journalArticle

McKay, JA, Douglas, JJ, Ross, VG, Curran, S, Ahmed, FY, Loane, JF, Murray, GI & McLeod, HL 2000, 'Expression of cell cycle control proteins in primary colorectal tumors does not always predict expression in lymph node metastases', Clinical Cancer Research, vol. 6, pp. 1113-1118.
McKay, J A ; Douglas, J J ; Ross, V G ; Curran, S ; Ahmed, F Y ; Loane, J F ; Murray, G I ; McLeod, H L . / Expression of cell cycle control proteins in primary colorectal tumors does not always predict expression in lymph node metastases. In: Clinical Cancer Research. 2000 ; Vol. 6. pp. 1113-1118.
@article{54f461fe884c4c678060717434869754,
title = "Expression of cell cycle control proteins in primary colorectal tumors does not always predict expression in lymph node metastases",
abstract = "Analysis of tumor markers focuses on expression in primary tumors with the assumption that this is representative of metastatic tumor, against which treatment is targeted. Few studies have compared the expression of such markers in primary and secondary tumors, In this study, several key genes involved in cell cycle regulation were investigated in colorectal tumors and corresponding lymph node metastases, The cell cycle regulators p53, cyclin D1, p21, p27, retinoblastoma protein (Rb), and proliferating cell nuclear antigen (PCNA) were examined in a series of 42 paired samples of primary colorectal and secondary lymph node tumors by immunohistochemistry. Expression of p53, p27, and Rb was similar in virtually all paired samples (p53, 38 of 42; p27, 39 of 42; Rb, 40 of 42), indicating that the pattern of these proteins in colorectal tumors may be used to predict that in lymph node tumors. It also suggests a lack of direct involvement in the metastatic process. A lower concordance for p21 and cyclin D1 staining was observed between primary and secondary tumors (p21, 19 of 42; cyclin D1, 22 of 42), p21 expression was more often observed in primary colorectal cancers, whereas cyclin D1 expression was more frequently seen in lymph node metastases, in keeping with the contrasting roles of these proteins as a cell cycle inhibitor (p21) and activator (cyclin D1). The PCNA-labeling index was found to vary considerably in a number of cases, thus limiting the ability to predict expression of this protein in lymph node metastases from the primary tumor. In addition, PCNA-labeling indices between paired samples were neither consistently higher nor lower, suggesting that the proliferative capacity of tumor cells is not directly related to their ability to metastasize.",
keywords = "NUCLEAR ANTIGEN PCNA, GENE-EXPRESSION, CANCER, P53, D1, ADENOCARCINOMAS, PROGNOSIS, IMMUNOHISTOCHEMISTRY, OVEREXPRESSION, PROLIFERATION",
author = "McKay, {J A} and Douglas, {J J} and Ross, {V G} and S Curran and Ahmed, {F Y} and Loane, {J F} and Murray, {G I} and McLeod, {H L}",
year = "2000",
language = "English",
volume = "6",
pages = "1113--1118",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",

}

TY - JOUR

T1 - Expression of cell cycle control proteins in primary colorectal tumors does not always predict expression in lymph node metastases

AU - McKay, J A

AU - Douglas, J J

AU - Ross, V G

AU - Curran, S

AU - Ahmed, F Y

AU - Loane, J F

AU - Murray, G I

AU - McLeod, H L

PY - 2000

Y1 - 2000

N2 - Analysis of tumor markers focuses on expression in primary tumors with the assumption that this is representative of metastatic tumor, against which treatment is targeted. Few studies have compared the expression of such markers in primary and secondary tumors, In this study, several key genes involved in cell cycle regulation were investigated in colorectal tumors and corresponding lymph node metastases, The cell cycle regulators p53, cyclin D1, p21, p27, retinoblastoma protein (Rb), and proliferating cell nuclear antigen (PCNA) were examined in a series of 42 paired samples of primary colorectal and secondary lymph node tumors by immunohistochemistry. Expression of p53, p27, and Rb was similar in virtually all paired samples (p53, 38 of 42; p27, 39 of 42; Rb, 40 of 42), indicating that the pattern of these proteins in colorectal tumors may be used to predict that in lymph node tumors. It also suggests a lack of direct involvement in the metastatic process. A lower concordance for p21 and cyclin D1 staining was observed between primary and secondary tumors (p21, 19 of 42; cyclin D1, 22 of 42), p21 expression was more often observed in primary colorectal cancers, whereas cyclin D1 expression was more frequently seen in lymph node metastases, in keeping with the contrasting roles of these proteins as a cell cycle inhibitor (p21) and activator (cyclin D1). The PCNA-labeling index was found to vary considerably in a number of cases, thus limiting the ability to predict expression of this protein in lymph node metastases from the primary tumor. In addition, PCNA-labeling indices between paired samples were neither consistently higher nor lower, suggesting that the proliferative capacity of tumor cells is not directly related to their ability to metastasize.

AB - Analysis of tumor markers focuses on expression in primary tumors with the assumption that this is representative of metastatic tumor, against which treatment is targeted. Few studies have compared the expression of such markers in primary and secondary tumors, In this study, several key genes involved in cell cycle regulation were investigated in colorectal tumors and corresponding lymph node metastases, The cell cycle regulators p53, cyclin D1, p21, p27, retinoblastoma protein (Rb), and proliferating cell nuclear antigen (PCNA) were examined in a series of 42 paired samples of primary colorectal and secondary lymph node tumors by immunohistochemistry. Expression of p53, p27, and Rb was similar in virtually all paired samples (p53, 38 of 42; p27, 39 of 42; Rb, 40 of 42), indicating that the pattern of these proteins in colorectal tumors may be used to predict that in lymph node tumors. It also suggests a lack of direct involvement in the metastatic process. A lower concordance for p21 and cyclin D1 staining was observed between primary and secondary tumors (p21, 19 of 42; cyclin D1, 22 of 42), p21 expression was more often observed in primary colorectal cancers, whereas cyclin D1 expression was more frequently seen in lymph node metastases, in keeping with the contrasting roles of these proteins as a cell cycle inhibitor (p21) and activator (cyclin D1). The PCNA-labeling index was found to vary considerably in a number of cases, thus limiting the ability to predict expression of this protein in lymph node metastases from the primary tumor. In addition, PCNA-labeling indices between paired samples were neither consistently higher nor lower, suggesting that the proliferative capacity of tumor cells is not directly related to their ability to metastasize.

KW - NUCLEAR ANTIGEN PCNA

KW - GENE-EXPRESSION

KW - CANCER

KW - P53

KW - D1

KW - ADENOCARCINOMAS

KW - PROGNOSIS

KW - IMMUNOHISTOCHEMISTRY

KW - OVEREXPRESSION

KW - PROLIFERATION

M3 - Article

VL - 6

SP - 1113

EP - 1118

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

ER -